<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Brief <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> is reported to cause selective neuronal <z:mp ids='MP_0001651'>necrosis</z:mp>, apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo>, silent <z:mpath ids='MPATH_124'>infarcts</z:mpath> and, when recurrent, <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> administration of <z:chebi fb="0" ids="9086">selegiline</z:chebi> and EGb 761 have been shown to have anti-apoptotic and neuroprotective effects in experimental <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Their daily use is currently advised to slow down <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> in patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Hence, unlike previous studies, we studied the neuroprotective action of <z:hpo ids='HP_0011010'>chronic</z:hpo> daily administration of these drugs in Swiss mice subjected to 30-min middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and 72 h of reperfusion since this model was reported to induce a slowly evolving <z:mpath ids='MPATH_124'>infarct</z:mpath> with profuse apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> area was evaluated by H&amp;E staining on coronal brain sections and, apoptotic cells were identified by histological criteria, terminal transferase-mediated d-<z:chebi fb="6" ids="15713">UTP</z:chebi> nick-end labeling (TUNEL) and by immunohistochemical detection of caspase-cleaved actin fragments (fractin) </plain></SENT>
<SENT sid="5" pm="."><plain>Fifty-one mice received daily intraperitoneal injections of 10 mg/kg <z:chebi fb="0" ids="9086">selegiline</z:chebi> (n=18) or 50 mg/kg EGb 761 (n=17) or equal volume of saline (n=16) for 10-14 days before but not on the day of insult </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, number of TUNEL- and fractin-positive cells were significantly reduced in treatment groups by 30, 42 and 51% (<z:chebi fb="0" ids="9086">selegiline</z:chebi>) and, 27, 27 and 29% (EGb 761), respectively </plain></SENT>
<SENT sid="7" pm="."><plain>These data suggest that prophylactic use of <z:chebi fb="0" ids="9086">selegiline</z:chebi> and EGb 761 could increase the brain's resistance to mild ischemic injury </plain></SENT>
</text></document>